Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls [Yahoo! Finance]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Yahoo! Finance
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: H.C. Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with a $20 price target after the company entered into an exclusive license agreement with privately held Biosion. Raymond James upgraded Weyerhaeuser (WY) to Outperform from Market Perform with a $32 price target, citing improving lumber fundamentals and "deep valuation discount." Raymond James upgraded PotlatchDeltic (PCH) to Outperform from Market Perform with a $45 price target. The firm sees a steadily improving backdrop forming for lumber price fundamentals. Piper Sandler upgraded GCM Grosvenor (GCMG) to Overweight from Neutral with a price target of $14, up from $12.50. There has been a "noticeable shift in sentiment" in the alternatives space in recent months and Piper does not believe the discounted va
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock.MarketBeat
- Aclaris Therapeutics files to sell 35.56M shares of common stock by selling shareholders [Seeking Alpha]Seeking Alpha
- Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
ACRS
Earnings
- 11/6/24 - Miss
ACRS
Sec Filings
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- ACRS's page on the SEC website